Form 4: Elanco Animal Health CEO Acquires Deferred Stock Units

Elanco Animal Health's CEO, Jeffrey N. Simmons, reports the acquisition of deferred stock units convertible to common stock.

Summary

• On August 9, 2024, Jeffrey N. Simmons, the President, CEO, and Director of Elanco Animal Health Inc., acquired 212.365 deferred stock units.
• These deferred stock units represent the right to receive one share of Elanco's common stock or the cash equivalent.
• The price of the deferred stock units was $13.04.
• Following the transaction, Simmons directly owns 2,933.7431 shares of Elanco's common stock.
• The deferred stock units will settle in cash or shares of Elanco common stock following termination of employment or during a specified future year, according to the Executive Deferral and Stock Match Plan.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment, simply reporting a transaction.

Future Outlook

The deferred stock units will settle in cash or shares of Elanco common stock following termination of employment or during a specified future year, according to the Executive Deferral and Stock Match Plan.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the holdings of key executives and their alignment with shareholder interests.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding executive compensation and ownership.

Key Dates